DUBLIN, Ireland, May 15, 2009 (GLOBE NEWSWIRE) -- Dr. John Fox, of Merrion Pharmaceuticals (“Merrion” or the “Company”), will address the 7th International Cancer Conference in Dublin today, and will speak about the very positive preliminary results from a multi centre Phase II study on Merrion’s Orazol(tm) drug (formerly known as MER 101). The study, conducted in hormone refractory prostate cancer patients with proven bone metastases, enrolled patients at sites in the U.S. and Europe.
